Sentences with phrase «studied drugs in»

In the new article, Adashi, who has studied the drug in the lab and the clinic and prescribed it thousands of times over the decades, traces the drug's development, path to market and ultimate impact.

Not exact matches

A small 2006 study found ginkgo was as effective as the drug donepezil for boosting attention and memory in people with mild to moderate Alzheimer's.

While the new mid-stage study results from DNDi were impressive (they showed cure rates of 96 % to 97 % even for the sickest patients and those with liver scarring), more late - stage trials will be necessary before the drug is available on a large scale in the developing world.

A new study published in the New England Journal of Medicine finds that Valeant Pharmaceuticals» infamous price hikes for a pair of heart drugs called nitroprusside and isoproterenol — whose prices were increased by 310 % and 720 %, respectively — had significant downstream effects on patient care.

Drug maker Takeda and U.K. - based partner Cognition Kit have shown promising (but preliminary) results in a study of their co-developed depression app.

A peer - reviewed study by researchers at the University of British Columbia and Simon Fraser University, published recently in The International Journal of Drug Policy, pegged the retail value of marijuana consumption in B.C. alone at between $ 443 million and $ 564 million.

Novo is advancing its clinical study of its next big hope in treating obesity: semaglutide, a new drug in the so - called GLP - 1 category which imitates an intestinal hormone that stimulates the production of insulin.

The striking example I focused on then was the cancer drug Avastin, developed by Genentech (now Roche)-- which, at the time, had been studied in at least 400 completed human clinical trials for various cancers.

The 2010 University of Brasilia study found that a drug is used in at least half of illegal abortions in Brazil.

Topics included: early reporting on inaccuracies in the articles of The New York Times's Judith Miller that built support for the invasion of Iraq; the media campaign to destroy UN chief Kofi Annan and undermine confidence in multilateral solutions; revelations by George Bush's biographer that as far back as 1999 then - presidential candidate Bush already spoke of wanting to invade Iraq; the real reason Bush was grounded during his National Guard days — as recounted by the widow of the pilot who replaced him; an article published throughout the world that highlighted the West's lack of resolve to seriously pursue the genocidal fugitive Bosnian Serb leader Radovan Karadzic, responsible for the largest number of European civilian deaths since World War II; several investigations of allegations by former members concerning the practices of Scientology; corruption in the leadership of the nation's largest police union; a well - connected humanitarian relief organization operating as a cover for unauthorized US covert intervention abroad; detailed evidence that a powerful congressional critic of Bill Clinton and Al Gore for financial irregularities and personal improprieties had his own track record of far more serious transgressions; a look at the practices and values of top Democratic operative and the clients they represent when out of power in Washington; the murky international interests that fueled both George W. Bush's and Hillary Clinton's presidential campaigns; the efficacy of various proposed solutions to the failed war on drugs; the poor - quality televised news program for teens (with lots of advertising) that has quietly seeped into many of America's public schools; an early exploration of deceptive practices by the credit card industry; a study of ecosystem destruction in Irian Jaya, one of the world's last substantial rain forests.

In a new study based on mice, scientists at Lancaster University found that a drug that goes after three diabetes - related targets «significantly reversed the memory deficit» in mice who got the drug, as measured by their performance in a maze test when compared to mice who didn't get the druIn a new study based on mice, scientists at Lancaster University found that a drug that goes after three diabetes - related targets «significantly reversed the memory deficit» in mice who got the drug, as measured by their performance in a maze test when compared to mice who didn't get the druin mice who got the drug, as measured by their performance in a maze test when compared to mice who didn't get the druin a maze test when compared to mice who didn't get the drug.

Says Bapty: «If a CRO is nimble and can evolve technology that can enable its clients to get a drug approved faster or to reduce the risk of a clinical study, or even save them development money in the long run, that company will find it has a long - term business plan.»

A separate study from JAMA Internal Medicine found that one of the most influential tools at drug and device makers» disposal is simply treating a doctor to a cheap meal in order to promote a product.

After fighting unsuccessfully to reverse generic drug laws last year, and the sudden resignation of its CEO, Shoppers Drug Mart has suffered a 17 % drop in «brand value,» to $ 2.6 billion, according to a study conducted by researcher Interbrdrug laws last year, and the sudden resignation of its CEO, Shoppers Drug Mart has suffered a 17 % drop in «brand value,» to $ 2.6 billion, according to a study conducted by researcher InterbrDrug Mart has suffered a 17 % drop in «brand value,» to $ 2.6 billion, according to a study conducted by researcher Interbrand.

On May 30, Gilead said it found in four late - stage studies that its its drug, bictegravir, wasn't inferior to ViiV's dolutegravir.

A new study using lab - engineered microtumors allowed doctors to better predict if a cancer drug treatment will work in a patient.

Speaking of checkpoint inhibitor drugs... Merck's star cancer immunotherapy treatment Keytruda is facing some troubling clinical trial incidents which have now compelled the Food and Drug Administration (FDA) to halt three studies of the drug in multiple myeloma, a rare blood cancer, after a number of patient deaDrug Administration (FDA) to halt three studies of the drug in multiple myeloma, a rare blood cancer, after a number of patient deadrug in multiple myeloma, a rare blood cancer, after a number of patient deaths.

But while thousands of clinical trials on immunotherapy drugs, of which many are predicted to fail, are springing up, the depth of information on neoantigen vaccines is much shallower: Just two studies on neoantigen vaccines for melanoma, recently profiled in Nature, were completed last year in Boston and Germany.

Swiss drug giant Novartis is partnering with California - based Science 37 in an effort to expand clinical study participation (while lowering the costs of such studies) through «virtual» trials.

The growing number of people who have the disease is troubling, because there are only four approved drugs that treat symptoms of the disease, and several hopeful treatments have failed key studies in 2017.

According to a 2015 research study in the Journal of American Medical Association, many new drugs approved by the Food and Drug Administration don't improve overall survival.

The study, just published in Science, showed that the creation of what the researchers are calling microtumors can help predict drug effectiveness in cancer patients better than the current standard method of testing the drugs on rodents.

That study is in people who are still considered cognitively healthy, so if the drug is able to prevent cognitive decline, it could be a breakthrough.

Bristol - Myers emphasized Opdivo's other successes and ongoing studies evaluating its effectiveness in combination with the company's other cancer drugs.

Both in practice and in his research, the Mexico City native is focused on improving the world, whether through studies on social enterprise and microfinance or a TED talk on brand management and Mexican drug cartels that accumulated more than 1 million views.

They've conducted studies in mice, which showed that the device was able to improve the results of the drug by twelve times.

Shares of Ligand Pharmaceuticals shed nearly 12 percent Tuesday after Amgen said its multiple myeloma drug, Kyprolis, did not outperform Takeda Pharmaceutical's Velcade in a late - stage study.

Shares of Ligand Pharmaceuticals plunged 12 percent Tuesday after Amgen said its multiple myeloma drug, Kyprolis, did not outperform Takeda Pharmaceutical's Velcade in a late - stage study.

But according to the Government Accountability Office (GAO) which did a study in 2013 on the drug shortage, other reasons include a lack of materials to make the drugs, as well as delays in getting government approval for new and experimental drugs.

Pagan said that a larger, more comprehensive study must be done before determining the drug's true impact, but if the drug's effectiveness is confirmed in such tests, nilotinib could become the first treatment to impede the killing of brain cells that's consistent with Parkinson's, according to NPR.

Bate published a study this year that found products ordered from certified sites (including Canada Drugs, a CIPA member) are identical to those purchased in the U.S..

In the study, mice were given food until they became obese, and were then fed the drug, which increases the cellular metabolism of obesity - linked white fat cells.

This study, which recently commenced, potentially positions Vascepa to be the first prescription grade EPA product to receive drug approval in China.

However, Spicer then signaled that the White House sees recreational pot very differently, with the press secretary even attempting to link recreational use of the drug to the abuse of opioid drugs across the U.S. (In fact, there has been little scientific evidence linking marijuana legalization to opioid use, with some studies actually showing a decrease in opioid overdoses in states where legal marijuana is availableIn fact, there has been little scientific evidence linking marijuana legalization to opioid use, with some studies actually showing a decrease in opioid overdoses in states where legal marijuana is availablein opioid overdoses in states where legal marijuana is availablein states where legal marijuana is available.)

Agios Pharmaceuticals shares plunged more than 18 percent after the company discontinued development of an experimental drug for rare blood disorder due to side effects seen in a study.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SDrug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the Sdrug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Study after study showed that DARE did not succeed in its primary goal of stopping youths from using dStudy after study showed that DARE did not succeed in its primary goal of stopping youths from using dstudy showed that DARE did not succeed in its primary goal of stopping youths from using drugs.

In an editorial accompanying the new study, Dr. Wilson Compton of the National Institute on Drug Abuse in Bethesda, Maryland, and colleagues say policymakers need to understand which parts of medical marijuana laws are tied with positive and negative effectIn an editorial accompanying the new study, Dr. Wilson Compton of the National Institute on Drug Abuse in Bethesda, Maryland, and colleagues say policymakers need to understand which parts of medical marijuana laws are tied with positive and negative effectin Bethesda, Maryland, and colleagues say policymakers need to understand which parts of medical marijuana laws are tied with positive and negative effects.

The project is to take place under the auspices of the Center for Supply Chain Studies, with the goal of bringing pharmaceutical firms into compliance with the Drug Supply Chain Security Act, passed in 2013.

The results, which mirror those of similar, small - scale studies of the illegal drug in recent years, come as MDMA is about to enter larger, Phase 3 trials this summer.

«We study the determinants of antimalarial drug quality in developing countries using data from the retail market in Uganda.

According to Living Goods, clients may also be reluctant to buy drugs from other private providers because of the risk of getting a counterfeit medicine.63 Living Goods sent us a study conducted at the midline of its RCT that claims that both availability of counterfeit drugs and drug prices decreased at private retailers in areas where CHPs worked.64 According to the study, about 37 % of private drug shops in the areas it studied sold fake ACT drugs, 65 and availabilty of fake ACTs was about 50 % lower among non-Living Goods sellers in the areas where Living Goods worked.66 Additional results on these potential effects will be made available when the full RCT is published.

Lilly outlined in July a likely multi-year delay for its experimental rheumatoid arthritis drug baricitinib, after the U.S. Food and Drug Administration declined to approve the drug, calling for an additional clinical stdrug baricitinib, after the U.S. Food and Drug Administration declined to approve the drug, calling for an additional clinical stDrug Administration declined to approve the drug, calling for an additional clinical stdrug, calling for an additional clinical study.

One of the great findings of this study is that you can be in a great company and be doing it in steel, in drug stores, or in grocery stores.

That market, however, could become more challenging if competing drugs, including Celgene's ozanimod, shine in late - stage studies.

Another migraine drug, lasmiditan, which Lilly picked up with its 2017 acquisition of Colucid Pharmaceuticals, is in late - stage clinical studies.

Directing emergency funds to areas hit by natural disasters had traditionally been quick bipartisan exercises, but that changed after Hurricane Katrina in 2005 — when the Republican Study Committee, a group of House conservatives, pushed spending cuts to compensate for the approximately $ 200 billion expected in Katrina relief — including cutting farm subsidies, Amtrak funding and postponing the Medicare prescription - drug bill Republicans had approved two years earlier.

That may come as a surprise amid hand - wringing about the spiraling cost of health care, but two new studies, one from research company IMS Health and one from pharmacy benefit manager Express Scripts, show that the amount of money Americans spend on prescription drugs went down in 2012 for the first time in decades.

On February 24th, the New York - based drug giant announced that Prevenar 13, a drug widely used to prevent infection in children, met its primary endpoint in a post-approval study consisting of 85,000 individuals aged 65 and older.

In early September, Alnylam stopped giving doses of its fitusiran drug for a rare bleeding disorder to patients enrolled in clinical studies after the death of a patienIn early September, Alnylam stopped giving doses of its fitusiran drug for a rare bleeding disorder to patients enrolled in clinical studies after the death of a patienin clinical studies after the death of a patient.